Two new drugs both oral, rather than injected may soon be available to combat multiple sclerosis.
Three studies, all being published early online Jan. 20 in the “New England Journal of Medicine”, find that the new drugs fingolimod and cladribine reduce relapse rates in people with relapsing-remitting multiple sclerosis (MS). Both drugs work by altering the immune system response.
However, as is often the case with immune-suppressing medications, there are concerns about side effects, including an increased risk of serious infections and possibly, cancer.
Full story: First Oral Medications for MS Show Promise